|
1
|
Bonenkamp JJ, Songun I, Hermans J, Sasako
M, Welvaart K, Plukker JT, van Elk P, Obertop H, Gouma DJ, Taat CW,
et al: Randomised comparison of morbidity after D1 and D2
dissection for gastric cancer in 996 Dutch patients. Lancet.
345:745–748. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ohtsu A, Shimada Y, Shirao K, Boku N,
Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, et
al: Randomized phase III trial of fluorouracil alone versus
fluorouracil plus cisplatin versus uracil and tegafur plus
mitomycin in patients with unresectable, advanced gastric cancer:
The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol.
21:54–59. 2003. View Article : Google Scholar
|
|
3
|
Yun J, Lee J, Park SH, Park JO, Park YS,
Lim HY and Kang WK: A randomised phase II study of combination
chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or
cisplatin and capecitabine (CX) in advanced gastric cancer. Eur J
Cancer. 46:885–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chu W, Pak BJ, Bani MR, Kapoor M, Lu SJ,
Tamir A, Kerbel RS and Ben-David Y: Tyrosinase-related protein 2 as
a mediator of melanoma specific resistance to
cis-diamminedichloroplatinum(II): therapeutic implications.
Oncogene. 19:395–402. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mizutani Y and Bonavida B: Overcoming
cis-diamminedichloroplatinum (II) resistance of human ovarian tumor
cells by combination treatment with cis-diamminedichloroplatinum
(II) and tumor necrosis factor-alpha. Cancer. 72:809–818. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu LZ, Zhou XD, Qian G, Shi X, Fang J and
Jiang BH: AKT1 amplification regulates cisplatin resistance in
human lung cancer cells through the mammalian target of
rapamycin/p70S6K1 pathway. Cancer Res. 67:6325–6332. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Meijer C, Mulder NH, Timmer-Bosscha H,
Sluiter WJ, Meersma GJ and de Vries EG: Relationship of cellular
glutathione to the cytotoxicity and resistance of seven platinum
compounds. Cancer Res. 52:6885–6889. 1992.PubMed/NCBI
|
|
8
|
Ozes ON, Mayo LD, Gustin JA, Pfeffer SR,
Pfeffer LM and Donner DB: NF-kappaB activation by tumour necrosis
factor requires the Akt serine-threonine kinase. Nature. 401:82–85.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
VanderWeele DJ, Zhou R and Rudin CM: Akt
up-regulation increases resistance to microtubule-directed
chemotherapeutic agents through mammalian target of rapamycin. Mol
Cancer Ther. 3:1605–1613. 2004.
|
|
11
|
Brognard J, Clark AS, Ni Y and Dennis PA:
Akt/protein kinase B is constitutively active in non-small cell
lung cancer cells andpromotes cellular survival and resistance to
chemotherapy and radiation. Cancer Res. 61:3986–3997.
2001.PubMed/NCBI
|
|
12
|
Falasca M: PI3K/Akt signalling pathway
specific inhibitors: a novel strategy to sensitize cancer cells to
anti-cancer drugs. Curr Pharm Des. 16:1410–1416. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Beckmann JS, Ye YZ, Anderson PG, et al:
Extensive nitration of protein tyrosines in human atherosclerosis
detected by immunohistochemistry. Biol Chem Hoppe Seyler.
375:81–88. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu QS, Zhang J, Liu M and Dong WG:
Lentiviral-mediated miRNA against liver-intestine cadherin
suppresses tumor growth and invasiveness of human gastric cancer.
Cancer Sci. 101:1807–1812. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Page C, Lin HJ, Jin Y, Castle VP, Nunez G,
Huang M and Lin J: Overexpression of Akt/AKT can modulate
chemotherapy-induced apoptosis. Anticancer Res. 20:407–416.
2000.PubMed/NCBI
|
|
16
|
Pommier Y, Sordet O, Antony S, Hayward RL
and Kohn KW: Apoptosis defects and chemotherapy resistance:
molecular interaction maps and networks. Oncogene. 23:2934–2949.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sekharam M, Zhao H, Sun M, Fang Q, Zhang
Q, Yuan Z, Dan HC, Boulware D, Cheng JQ and Coppola D: Insulin-like
growth factor 1 receptor enhances invasion and induces resistance
to apoptosis of colon cancer cells through the Akt/Bcl-x(L)
pathway. Cancer Res. 63:7708–7716. 2003.PubMed/NCBI
|
|
18
|
Kandasamy K and Srivastava RK: Role of the
phosphatidylinositol 3′-kinase/PTEN/Akt kinase pathway in tumor
necrosis factor-related apoptosis-inducing ligand-induced apoptosis
in non-small cell lung cancer cells. Cancer Res. 62:4929–4937.
2002.
|
|
19
|
Liu Y, Chen L, Ko TC, Fields AP and
Thompson EA: Evi1 is a survival factor which conveys resistance to
both TGFbeta- and taxol-mediated cell death via PI3K/AKT. Oncogene.
25:3565–3575. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Campbell RA, Bhat-Nakshatri P, Patel NM,
Constantinidou D, Ali S and Nakshatri H: Phosphatidylinositol
3-kinase/AKT- mediated activation of estrogen receptor alpha: a new
model for anti-estrogen resistance. J Biol Chem. 276:9817–9824.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamasaki F, Johansen MJ, Zhang D,
Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K,
Mills GB, Hortobagyi GN and Ueno NT: Acquired resistance to
erlotinib in A-431 epidermoid cancer cells requires down-regulation
of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res.
67:5779–5788. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xia W, Mullin RJ, Keith BR, Liu LH, Ma H,
Rusnak DW, Owens G, Alligood KJ and Spector NL: Anti-tumor activity
of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation
ofEGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene.
21:6255–6263. 2002. View Article : Google Scholar : PubMed/NCBI
|
